SCHEMBL1243313

SCHEMBL1243313

CCOC(=O)c1cn(C2CCOC2)c2cc(NC3CCCCC3)c(F)cc2c1=O

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
GAA P10253 1/20 0.51
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 4/20 0.46
HPGD P15428 3/20 0.46
HSD17B10 Q99714 3/20 0.46
ADRB2 P07550 1/20 0.43
HTR3A P46098 4/20 0.41
ALOX15 P16050 1/20 0.40
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
FOXO1 Q12778 1/20 0.39
P2RX7 Q99572 2/20 0.38
PDE4B Q07343 1/20 0.38
IL1B P01584 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1243820 0.89 KMT2A (0.54) KMT2AMEN1GAAKDM4EALDH1A1
SCHEMBL1243388 0.88 KMT2A (0.53) KMT2AKDM4EALDH1A1HPGDHSD17B10
SCHEMBL1242804 0.86 KMT2A (0.50) KMT2AMEN1GAAKDM4EALDH1A1
SCHEMBL1242693 0.86 KMT2A (0.53) KMT2AMEN1GAAKDM4EALDH1A1
SCHEMBL1242538 0.84 KMT2A (0.51) KMT2AMEN1GAAKDM4EALDH1A1
SCHEMBL4174142 0.82 MEN1 (0.46) KMT2AMEN1GAAKDM4EALDH1A1
SCHEMBL1243978 0.82 MEN1 (0.51) KMT2AMEN1GAAKDM4EALDH1A1
SCHEMBL9270695 0.80 KMT2A (0.57) KMT2AMEN1KDM4EALDH1A1HPGD
SCHEMBL1241150 0.79 KMT2A (0.55) KMT2AMEN1GAAKDM4EALDH1A1
SCHEMBL1243157 0.79 KDM4E (0.56) KMT2AMEN1GAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879878-B2 such as {2-[({[7-(cyclohexylamino)-6-fluoro-4-oxo-1-[(3S)-tetrahydrofuran-3-yl]-1,4-dihydroquinolin-3-yl}carbonyl)amino]ethyl}phosphonic acid, used as platelet aggregation inhibitor and purinergic receptor (P2Y12) inhibitors; therapy for circulatory diseases involving thrombosis via platelet aggregation ASTELLAS PHARMA INC. (JP) 2011-02-01 US disclosed
US-20090124617-A1 QUINOLONE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-05-14 US disclosed
US-7488739-B2 Quinolone derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2009-02-10 US disclosed
US-20060148806-A1 Quinolone derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2006-07-06 US disclosed
EP-1650192-A1 QUINOLONE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2006-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124617-A1 QUINOLONE DERIVATIVE OR SALT THEREOF THPO, ABL1, GMPS KMT2A 2659/4885MEN1 2643/4885GAA 1758/4885
US-20060148806-A1 Quinolone derivative or salt thereof THPO, ABL1, GMPS KMT2A 2659/4885MEN1 2643/4885GAA 1758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.